Skip to content
AnalystLens
Back to BBIOIncome Statement

BridgeBio Pharma Net Income 2017-2026 | BBIO

Annual FY2017–FY2025 · quarterly through Q3 FY2026

Latest annual · FY2025

−$724.9M

−35.3%YoY vs FY2024Source: 10-KFY2025

From −$30.6M in FY2017 to −$724.9M in FY2025.

By quarter▲▼ vs a year before
Fiscal yearQ1Q2Q3Q4
FY26−$164M+2.0%−$152M+16.3%−$83M+54.6%Not reported
FY25−$167M−375.4%−$182M−147.6%−$183M−12.8%−$193M+27.2%
FY24−$35M+74.9%−$73M+53.5%−$162M+8.5%−$265M−57.6%
FY23−$140M+28.6%−$158M−1502.1%−$177M−28.9%−$168M−22.2%
FY22−$196M−20.4%−$10M+89.8%−$137M+11.9%−$138M+6.5%

Shaded by size: darkest is the largest quarter shown; ringed is the latest reported; a dash marks a quarter with no separate figure. Each quarter sits by its period-end date.

Key Statistics

Trend DirectionStable
CAGR

N/A

FY2020
−$448.7M
FY2025
−$724.9M

5 years selected · on the chart

Net Income History

Year-over-year comparison from 10-K annual reports

  1. −$724.9M
YoY changeLargest recent move−327.8%in FY18Latest −35.3%

1 older move runs past ±150% (largest −327.8%); point at, tap or drag across the bars to read one.

Net Income, period by period

PeriodValueChangeSource
FY2025−$724.9M−35.3%10-K
FY2024−$535.8M+16.7%10-K
FY2023−$643.2M−33.7%10-K
FY2022−$481.2M+14.5%10-K
FY2021−$562.5M−25.4%10-K
FY2020−$448.7M−72.2%10-K
FY2019−$260.6M−99.3%10-K
FY2018−$130.7M−327.8%10-K
FY2017−$30.6M—10-K

What is net income?

Net income can be defined as the company's total earnings or profit. It is calculated as revenues minus all expenses including cost of goods sold, operating expenses, interest, and taxes.

What is BridgeBio Pharma's current net income?

BridgeBio Pharma (BBIO) annual net income for 2025 was $-724.9M, a 35.31% decline from 2024. BridgeBio Pharma net income for the quarter ending September 30, 2026 was $-83.0M.

What was BridgeBio Pharma's net income in 2024?

BridgeBio Pharma annual net income for 2024 was $-535.8M, a 16.70% increase from 2023.

What was BridgeBio Pharma's net income in 2023?

BridgeBio Pharma annual net income for 2023 was $-643.2M, a 33.67% decline from 2022.

Company
BridgeBio Pharma
Ticker
BBIO
Sector
Healthcare
Industry
Pharmaceutical Preparations